By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy.

Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-STAR part B [abstract 195]

Journal

Presented at the Liver Meeting 2017; October 20–24, 2017; Washington, DC

Authors

Type of Article

Conference Proceedings